Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
Background: There were some reports of peripheral artery occlusive disease (PAOD) associated with nilotinib usage in chronic myeloid leukemia (CML). These complications in other tyrosine kinase inhibitors are revealed as unknown. Materials and methods: We determined the prevalence of PAOD in patient...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-12-01
|
| Series: | Clinical Medicine Insights: Cardiology |
| Online Access: | https://doi.org/10.1177/1179546817747258 |
| _version_ | 1818970302459150336 |
|---|---|
| author | Thanawat Rattanathammethee Adisak Tantiworawit Ekarat Rattarittamrong Chatree Chai-Adisaksopha Sasinee Hantrakool Arintaya Phrommintikul Wanwarang Wongcharoen Siriluck Gunaparn Lalita Norasetthada |
| author_facet | Thanawat Rattanathammethee Adisak Tantiworawit Ekarat Rattarittamrong Chatree Chai-Adisaksopha Sasinee Hantrakool Arintaya Phrommintikul Wanwarang Wongcharoen Siriluck Gunaparn Lalita Norasetthada |
| author_sort | Thanawat Rattanathammethee |
| collection | DOAJ |
| description | Background: There were some reports of peripheral artery occlusive disease (PAOD) associated with nilotinib usage in chronic myeloid leukemia (CML). These complications in other tyrosine kinase inhibitors are revealed as unknown. Materials and methods: We determined the prevalence of PAOD in patients with CML as compared with matched-control population by cross-sectional case-control study. Peripheral artery occlusive disease was screened by ankle-brachial index (ABI). Results: In total, 78 CML and 156 matched-control patients were included. The median age was 55 years. In all, 61 (78.2%) were on imatinib and 13 (16.7%) were on nilotinib, whereas 4 patients (5.2%) were on dasatinib. Prevalence of low ABI (<0.9) was 9.0%, and nilotinib users had the highest prevalence of low ABI of 30.7%. All cases with low ABI were not shown to be clinically overt of PAOD. There were well-balanced characteristics between cases of CML and matched control except in higher levels of hypercholesterolemia in the control. Interestingly, CML had more amounts of pathologic ABI than the control (odds ratio: 2.09, 95% confidence interval: 0.71-6.21), and diagnosis of diabetes found it to be independent of the risk of PAOD. Conclusions: Peripheral artery occlusive disease was higher among patients with CML than the control, especially in patients who had diabetes. |
| first_indexed | 2024-12-20T14:34:19Z |
| format | Article |
| id | doaj.art-d39bd578cc7743168cf1d9b021918795 |
| institution | Directory Open Access Journal |
| issn | 1179-5468 |
| language | English |
| last_indexed | 2024-12-20T14:34:19Z |
| publishDate | 2017-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Cardiology |
| spelling | doaj.art-d39bd578cc7743168cf1d9b0219187952022-12-21T19:37:31ZengSAGE PublishingClinical Medicine Insights: Cardiology1179-54682017-12-011110.1177/1179546817747258Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control StudyThanawat Rattanathammethee0Adisak Tantiworawit1Ekarat Rattarittamrong2Chatree Chai-Adisaksopha3Sasinee Hantrakool4Arintaya Phrommintikul5Wanwarang Wongcharoen6Siriluck Gunaparn7Lalita Norasetthada8Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandBackground: There were some reports of peripheral artery occlusive disease (PAOD) associated with nilotinib usage in chronic myeloid leukemia (CML). These complications in other tyrosine kinase inhibitors are revealed as unknown. Materials and methods: We determined the prevalence of PAOD in patients with CML as compared with matched-control population by cross-sectional case-control study. Peripheral artery occlusive disease was screened by ankle-brachial index (ABI). Results: In total, 78 CML and 156 matched-control patients were included. The median age was 55 years. In all, 61 (78.2%) were on imatinib and 13 (16.7%) were on nilotinib, whereas 4 patients (5.2%) were on dasatinib. Prevalence of low ABI (<0.9) was 9.0%, and nilotinib users had the highest prevalence of low ABI of 30.7%. All cases with low ABI were not shown to be clinically overt of PAOD. There were well-balanced characteristics between cases of CML and matched control except in higher levels of hypercholesterolemia in the control. Interestingly, CML had more amounts of pathologic ABI than the control (odds ratio: 2.09, 95% confidence interval: 0.71-6.21), and diagnosis of diabetes found it to be independent of the risk of PAOD. Conclusions: Peripheral artery occlusive disease was higher among patients with CML than the control, especially in patients who had diabetes.https://doi.org/10.1177/1179546817747258 |
| spellingShingle | Thanawat Rattanathammethee Adisak Tantiworawit Ekarat Rattarittamrong Chatree Chai-Adisaksopha Sasinee Hantrakool Arintaya Phrommintikul Wanwarang Wongcharoen Siriluck Gunaparn Lalita Norasetthada Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study Clinical Medicine Insights: Cardiology |
| title | Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study |
| title_full | Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study |
| title_fullStr | Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study |
| title_full_unstemmed | Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study |
| title_short | Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study |
| title_sort | peripheral artery occlusive disease among patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors a cross sectional case control study |
| url | https://doi.org/10.1177/1179546817747258 |
| work_keys_str_mv | AT thanawatrattanathammethee peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT adisaktantiworawit peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT ekaratrattarittamrong peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT chatreechaiadisaksopha peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT sasineehantrakool peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT arintayaphrommintikul peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT wanwarangwongcharoen peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT siriluckgunaparn peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy AT lalitanorasetthada peripheralarteryocclusivediseaseamongpatientswithchronicmyeloidleukemiareceivingtyrosinekinaseinhibitorsacrosssectionalcasecontrolstudy |